Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.33 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.33 |
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26270123 | 1.00 | SLC6A1 (0.33) | SLC6A1SLC6A11TYMP | |
| SCHEMBL27094916 | 1.00 | SLC6A1 (0.33) | SLC6A1SLC6A11TYMP | |
| SCHEMBL12765859 | 0.86 | TYMP (0.32) | SLC6A1SLC6A11TYMP | |
| SCHEMBL13374809 | 0.86 | TYMP (0.32) | SLC6A1SLC6A11TYMP | |
| SCHEMBL31328318 | 0.86 | SLC6A1 (0.31) | SLC6A1SLC6A11TYMP | |
| SCHEMBL13329991 | 0.86 | TYMP (0.32) | SLC6A1SLC6A11TYMP | |
| SCHEMBL24829632 | 0.86 | TYMP (0.32) | SLC6A1SLC6A11TYMP | |
| SCHEMBL25747161 | 0.86 | TYMP (0.32) | SLC6A1SLC6A11TYMP | |
| SCHEMBL14064222 | 0.85 | TYMP (0.31) | TYMP | |
| SCHEMBL22509393 | 0.85 | TYMP (0.33) | SLC6A1SLC6A11TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250297258-A1 | OLIGONUCLEOTIDE-BASED DELIVERY VEHICLE FOR OLIGONUCLEOTIDES AGENTS AND METHODS OF USE THEREOF | RACTIGEN THERAPEUTICS (CN) | 2025-09-25 | — | — | US | claimed |
| US-20250297258-A1 | OLIGONUCLEOTIDE-BASED DELIVERY VEHICLE FOR OLIGONUCLEOTIDES AGENTS AND METHODS OF USE THEREOF | RACTIGEN THERAPEUTICS (CN) | 2025-09-25 | — | — | US | disclosed |
| US-10975423-B2 | Methods for true isothermal strand displacement amplification | ELITECHGROUP, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200040387-A1 | METHODS FOR TRUE ISOTHERMAL STRAND DISPLACEMENT AMPLIFICATION | ELITECHGROUP, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-6828434-B2 | Such as 5-O-4,4'dimethoxytrityl-1,2-dideoxy-1-(o-nitrobenzyl)-D-ribofuranose-3-O-(2 -cyanoethyl-N, N'-diisopropyl) phosphoramidite for enhancing cellular uptake, lipophilicity, and retention of oligonucleotides within; antisense therapy | ISIS PHARMACEUTICALS, INC. | 2004-12-07 | — | — | US | disclosed |
| US-20030153737-A1 | Oligonucleotide and nucleotide amine analogs, methods of synthesis and use | ISIS PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| US-6495671-B1 | Oligonucleotide and nucleotide amine analogs, methods of synthesis and use | ISIS PHARMACEUTICALS, INC. | 2002-12-17 | — | — | US | disclosed |
| EP-0635023-B1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2002-02-06 | — | — | EP | disclosed |
| US-6235886-B1 | OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. | 2001-05-22 | — | — | US | disclosed |
| US-5834607-A | FOR ENHANCED CELLULAR UPTAKE OF OLIGONUCLEOTIDES; ANTISENSE THERAPY | ISIS PHARMACEUTICALS, INC. (US) | 1998-11-10 | — | — | US | disclosed |
| US-5811534-A | PURINE-BASED COMPOUNDS FOR INCLUSION INTO OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1998-09-22 | — | — | US | disclosed |
| US-5719271-A | HYBRIDS; GENETIC ENGINEERING | ISIS PHARMACEUTICALS, INC. (US) | 1998-02-17 | — | — | US | disclosed |
| US-5681941-A | GENETIC ENGINEERING; CROSSLINKING OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1997-10-28 | — | — | US | disclosed |
| US-5543507-A | BONDING STRANDS OR ONE STRAND AT DIFFERENT SITES; RNA MIMICS FIXED IN SPATIAL CONFORMATION; NUCLEASE RESISTANT MIMICS OF BINDING RECEPTORS FOR NUCLEIC ACID-BINDING PROTEINS; 5-LIPOXYGENASE INHIBITORS; DIAGNOSIS; ANALYZING | ISIS PHARMACEUTICALS, INC. (US) | 1996-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250297258-A1 | OLIGONUCLEOTIDE-BASED DELIVERY VEHICLE FOR OLIGONUCLEOTIDES AGENTS AND METHODS OF USE THEREOF | MTREX, DCLRE1B, ADAR | SLC6A1 4633/4885SLC6A11 4520/4885TYMP 1700/4885 |
| US-20030153737-A1 | Oligonucleotide and nucleotide amine analogs, methods of synthesis and use | NUDT1, ADAR, NT5C3B | SLC6A1 2918/4885SLC6A11 2542/4885TYMP 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.